Sodium propionate with immunotherapy for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding sodium propionate (a food additive) to standard immunotherapy and chemotherapy can help treat stomach cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have been diagnosed with stomach cancer (adenocarcinoma) that cannot be removed by surgery.
- You are about to start or are already receiving immunotherapy (anti-PD-1) combined with chemotherapy as your first treatment.
- You are generally healthy, not pregnant or breastfeeding, and have no other active cancers.
- You have not taken part in any other drug trial in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new immunotherapy drug (SHR-1701) combined with standard chemoradiotherapy for people with advanced stomach or esophagus cancer that cannot be surgically removed. The goal is to see if adding this immune treatment helps control the tumor better than standard treatments alone.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and radiation for stomach cancer that hasn't been treated before. The goal is to see if this approach can shrink tumors and help you live longer.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs before surgery for people with resectable gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Gastric Cancer (GC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.